• Name
  • Description
  • Pricings
  • Quantity
  • HERV-K
  • Endogenous retrovirus K Envelope Human Recombinant
  • Shipped with Ice Packs

Catalogue number



HERVK is related with several tumors such as passenger virus, and anti-Retroviral therapy against amyotrophic lateral sclerosis/ALS has exhibited to decrease the symptoms of amyotrophic lateral sclerosis/ALS. High counts of viral sequences exist in the human genome but stay silent. Though, in pathological conditions, these viruses are produced. Human Endogenous Retrovirus-K, is produced in neurons of a subpopulation of patients with amyotrophic lateral sclerosis/ALS, a progressive neurodegenerative disease. The envelope protein of this HERV results in degeneration of neurons, and transgenic animals producing this protein advance an ALS-like syndrome triggered by nucleolar dysfunction in motor neurons. Reactivation of the HERVK is controlled by the transcription factor TDP-43. Therefore, therapeutic tactics against this virus alter the course of the disease.


The E.Coli derived HERV-K recombinant truncated protein is fused to a Six histidine tag at C-terminus and has a MW of 51.5kDa (pI 9.06).


Escherichia Coli.


Protein is >90% pure as determined by SDS PAGE.

Physical Appearance

Sterile Filtered clear solution.


10mM Phosphate buffer pH 7.2.


HERV-K although stable at 4°C for 1 week, should be stored below -18°C.

Please prevent freeze thaw cycles.


Detection of Human Endogenious Retrovirus K in individuals is untested.

Safety Data Sheet


ProSpec's products are furnished for LABORATORY RESEARCH USE ONLY.They may not be used as drugs,agricultural or pesticidal products, food additives or household chemicals.

Back to Top